Title

Effect of amlodipine and telmisartan on bone metabolism markers in newly diagnosed hypertensive patients

Authors

Kamlesh Garg¹, Perumal Raveendranath¹, Sameer Gulati², Sufian Zaheer¹, Amita Yadav¹ & Ruchika Nandha³,*

Affiliation

¹Department of Pathology, Pharmacology, & Biochemistry, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India; ²Department of Medicine, Lady Hardinge Medical College, New Delhi, India; ³Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences & Hospital, Panjab University, Chandigarh, India; *Corresponding author

Email

Kamlesh Garg - E-mail: drkamlesh2002@yahoo.com

Perumal Raveendranath - E-mail: perumal.raveendranath@gmail.com

Sameer Gulati - E-mail: drsameergulati@gmail.com

Sufian Zaheer - E-mail: sufianzaheer@gmail.com

Amita Yadav - E-mail: dramita.md@gmail.com

Ruchika Nandha - E-mail: rnandha23@yahoo.co.in

Article Type

Research Article

Date

Received June 1, 2026; Revised June 30, 2026; Accepted June 30, 2026, Published June 30, 2026

Abstract

Hypertension may adversely affect bone health, but the skeletal effects of commonly prescribed antihypertensive drugs remain inadequately understood. In this 24-week prospective study, 96 newly diagnosed Stage I hypertensive patients received either Amlodipine (5–10 mg) or Telmisartan (40–80 mg), with serial assessment of bone metabolism markers. Both drugs achieved comparable blood pressure control throughout the study period. Telmisartan significantly reduced PTH and IL-6 levels while enhancing BS-ALP and transiently increasing osteocalcin, whereas Amlodipine demonstrated only a temporary rise in BS-ALP. Thus, data shows the telmisartan may provide additional benefits on bone remodeling and skeletal health in hypertensive patients at risk of fragility.

Keywords

Bone metabolism markers, bone turnover markers, amlodipine, telmisartan, hypertension, parathormone, osteocalcin, interleukin-6, bone-specific alkaline phosphatase

Citation

Garg et al. Bioinformation 22(6): 3768-3772 (2026)

Edited by

Ruby Singh  

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.